Biocon Files IND For Oral Insulin In U.S.; Launch In India Likely In 2011
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Amidst a row over the safety and absorption profile of inhaled insulins, Biocon - which steadily advanced its orally-delivered insulin IN-105 into Phase III trials in India - has now filed an investigational new drug application with U.S. FDA
You may also be interested in...
Biocon's Oral Insulin Fails To Meet Primary Endpoint; Unfazed, Company Says Stage Set For Partnering Talks With Global Pharma
MUMBAI - India's flagship biotechnology company Biocon suffered a significant setback to its most ambitious research project - an orally delivered insulin - that failed to meet its primary end point of lowering HbA1c levels by 0.7 percent in a clinical study concluded recently in India
Biocon's Oral Insulin Fails To Meet Primary Endpoint; Unfazed, Company Says Stage Set For Partnering Talks With Global Pharma
MUMBAI - India's flagship biotechnology company Biocon suffered a significant setback to its most ambitious research project - an orally delivered insulin - that failed to meet its primary end point of lowering HbA1c levels by 0.7 percent in a clinical study concluded recently in India
Biocon's Oral Insulin Fails To Meet Primary Endpoint
Unfazed, company says stage set for partnering talks with global pharma.